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Abstract
Background: The risk of influenza infection depends on biological characteristics, individual or collective behaviors
and the environmental context. The Cohorts for Pandemic Influenza (CoPanFlu) France study was set up in 2009
after the identification of the novel swine-origin A/H1N1 pandemic influenza virus. This cohort of 601 households
(1450 subjects) representative for the general population aims at using an integrative approach to study the risk
and characteristics of influenza infection as a complex combination of data collected from questionnaires regarding
sociodemographic, medical, behavioral characteristics of subjects and indoor environment, using biological samples
or environmental databases.
Methods/Design: Households were included between December 2009 and July 2010. The design of this study
relies on systematic follow-up visits between influenza seasons and additional visits during influenza seasons, when
an influenza-like illness is detected in a household via an active surveillance system. During systematic visits, a nurse
collects individual and environmental data on questionnaires and obtains blood samples from all members of the
household. When an influenza-like-illness is detected, a nurse visits the household three times during the 12
following days, and collects data on questionnaires regarding exposure and symptoms, and biological samples
(including nasal swabs) from all subjects in the household. The end of the follow-up period is expected in fall 2012.
Discussion: The large amount of data collected throughout the follow-up will permit a multidisciplinary study of
influenza infections. Additional data is being collected and analyzed in this ongoing cohort. The longitudinal
analysis of these households will permit integrative analyses of complex phenomena such as individual, collective
and environmental risk factors of infection, routes of transmission, or determinants of the immune response to
infection or vaccination.
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Background
The first human cases of influenza caused by a novel
swine-origin A/H1N1 pandemic influenza virus variant
(H1N1pdm) were reported in Mexico and the United
States in April 2009 [1]. Given the rapid spread of this
virus and considering the likelihood of its pandemic ex-
tent – confirmed by the World Health Organization
(WHO) on June 11, 2009 [2] – the Cohorts for Pan-
demic Influenza (CoPanFlu) international consortium
was initiated to study individual and collective determi-
nants of H1N1pdm influenza infection across countries
by setting up prospective cohorts of households, fol-
lowed for 2 years in 6 countries or regions of the world:
metropolitan France, Mali [3], Bolivia, Laos, Reunion Is-
land [4] and Djibouti. The CoPanFlu-France cohort, set
up in metropolitan general population, is part of the
CoPanFlu international consortium and its protocol
served as a blueprint for the other international cohorts.
Several studies already reported risk factors for sea-
sonal or pandemic influenza infection in households.
These studies focused on including individual character-
istics of index patients and their household contacts [5-
10] or hygiene measures as predictors of secondary
household infections [11,12]. In addition to household
studies, risk factors of seasonal influenza infections have
been studied in relation to characteristics of social con-
tacts [13] or baseline serological status of the host [14].
However, to our knowledge, no attempt was made to
study the risk of influenza infection as a complex com-
bination of biological characteristics (including immun-
ity), individual or collective behaviors and environmental
context. This integrative approach, in which epidemio-
logical data is comprehensively collected and analyzed, is
currently developed for non-communicable diseases and
relies on methods derived from Genome-Wide Associ-
ation Studies (GWAS) [15,16]. To achieve our objec-
tives, we developed a multidisciplinary approach, with
an original design involving data collection on subjects
and their environment and biological samples.
Methods/Design
Sampling
This cohort was designed to assess the relative risk of in-
fection by the H1N1pdm virus. We first intended to in-
clude 1000 households (about 2100 subjects) which
would have permitted to detect covariates associated to
a relative risk ≥ 1.4 with a 80% power and 5% signifi-
cance, assuming a cumulative incidence of 10% and
intra-household correlation of 0.3.
Households were sampled using a random tele-
phonic procedure (Mitofsky–Waksberg design [17]) in
a stratified geographical sampling scheme, aimed at in-
cluding a sample of subjects as close as possible to the
French general population [18,19]. Forty addresses
were drawn from the national directory. These
addresses defined the centers of 40 areas inside which
subjects were eligible. The limits of these areas were
defined as the smallest circle including 130,000 house-
hold addresses in the public directory. The size of
these areas varied (5 to 5000 km2) according to popula-
tion density (see Figure 1). In each area, two lists of
households were drawn:
 A “landline” list of 25 households: these households
were chosen as those with the phone number
immediately following a landline number drawn in
this area. Since landline numbers are geographically
allocated, this method ensured reaching households
who chose not to be listed in the national directory.
 A “mobile phone” list of 7 households: these
households were directly drawn in the national
directory, in order to reach households without a
fixed phone.
Addresses were iteratively drawn from the 40 lists of
130,000 households each and these households were
phoned to present the study and, upon meeting eligibil-
ity criteria, were sent a written description of the study.
A household was considered as “pre-included” when a
referent member sent back a filled form to confirm his
agreement. According to this method, 1,280 households
were pre-included, i.e. agreed to be visited by a nurse for
an inclusion visit involving all household members. We
anticipated that 20% of pre-included households would
finally decline to participate in the cohort.
Eligibility criteria
A household was defined as a person or group of people
occupying the same domicile. All households were eli-
gible to participate in the cohort, provided at least one
member was over 18 years of age and French-speaking.
A household member was defined as a person living at
least half his/her time in the household. All household
members were eligible, regardless of age. The inclusion
of a household required the participation of all mem-
bers: the refusal of one or more member(s) prevented
the inclusion of other members.
Participants
Five thousand one hundred and two households were
contacted by phone in order to achieve our targeted
number of 1280 pre-included households (see Figure 2).
The rate of contacted eligible households who agreed to
be pre-included varied from 17% to 34% across the 40
areas. The main reasons for non-participation were lack
of time and expected difficulty to collect blood samples
from children.
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Six hundred and seven households were visited by a
nurse for an inclusion visit, among which six finally did
not agree to participate (refusal of at least one member
after receiving more detailed information on the study).
Data was collected on the 601 remaining households
(1450 subjects). According to population census data
[20], these households had sociodemographic character-
istics close to the general population (see Additional file 1:
Figure S1 and Additional file 1: Tables S1–S6 for details).
Data collection
The main objective of this study was to identify individ-
ual and collective determinants of H1N1pdm infection;
therefore we tried to collect comprehensive data about
subjects and their environment, in addition to biological
samples. Several household visits are carried on by
nurses for this purpose (see Figure 3 for details).
 Inclusion visits
During the inclusion visit, nurses collected from
all subjects detailed data regarding medical
history, vaccination and preventive measures
against influenza, smoking habits, socioeconomic
status, risk perception and beliefs, frequency and
characteristics of meetings with other people and
housing (personal room, house or apartment). As
the households’ addresses were geocoded, we
were able to get additional information from
public databases regarding the immediate
surrounding environment of households. An
overview of data collected from questionnaires at
entry in the cohort is shown in Figure 4. Blood
samples were collected and centralized for
serological analyses. For subjects over 10 years, a
heparinated tube was also collected to study
cellular immunity, as well as a blood sample
dedicated to transcript analyses.
 Systematic yearly visits
After the inclusion visit, systematic follow-up visits
are carried on between influenza seasons. During a
systematic visit, a nurse collects or updates
individual and environmental data on
questionnaires, completes previously missing data,
and obtains blood samples from all members of the
household. Two waves of systematic follow-up
visits have already occurred (summer-fall 2010 and
2011). A third wave is expected by the end of the
second year of follow-up (summer 2012).
Population density
(inhabitants / km2)
26,000
1,000
500
200
100
60
30
15
0
Figure 1 Distribution of included households in relation to density of population (total: N = 601). White discs represent the 40 areas of
the study. Overlapping areas are merged.
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 Influenza-like illness (ILI) visits
During the influenza season (as defined by the
French surveillance network [21]), we use an
active surveillance system order to detect ILIs: all
households are called by an interactive voice
response system (IVRS) weekly and are asked if
any subject has symptoms of ILI (fever ≥ 37.8°C
associated with cough or sore throat, as defined
by the CDC [22]). A free phone number is given
to subjects to report symptoms spontaneously
between two weekly calls. In case of reported ILI,
symptoms are validated by the study team and
then three “ILI visits” are organized: nurses visit
the household within 48 h after the onset of
symptoms, then 3–6 days and 8–12 days after the
onset.
 During these visits, a detailed questionnaire collects
data about the circumstances of possible exposure to
influenza viruses and the chronology of symptoms
(if any) in all subjects. Nasal swabs are collected
from all subjects. A stool sample and a throat swab
are also collected from subjects with ILI, as well as a
blood sample from those over 10 years of age.
Moreover, a self-swab procedure is previously sent
to the households in order to collect virological
samples when a visit by a nurse within the first 48 h
Figure 2 Flow diagram until the 2nd systematic follow-up visit.
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is not possible. Nasal swabs are used to identify
various respiratory viruses by PCR and biochips
allowing for multiple diagnosis tests.
 This series of three visits can occur several times in
the same household during an influenza season.
There were 23 ILI alerts during the 2009–2010
season (as households were still being included) and
143 during the 2010-2011 season, all of which
triggered up to three ILI visits.
 Vaccination visits
In order to update serological information, a
blood sample was collected from subjects who
had an influenza vaccination, between 2 and
4 weeks following this vaccination. There was one
vaccination visit following the inclusion visits; 29
vaccination visits were conducted following the
first wave of follow-up visits and 69 following the
second wave.
Timeline
The cohort was initially designed to include households be-
fore the 2009 pandemic season and to follow subjects dur-
ing the two subsequent influenza seasons. We obtained
funding in June 2009, the cohort protocol and question-
naires were finalized in July 2009, and the protocol obtained
ethical approval on September 8, 2009. Households were
pre-included between September 25 and December 17,
2009 and inclusion visits began on December 4, 2009 – as
the final administrative authorizations were obtained. The
inclusion period was extended until July 31, 2010, in order
to get a relevant sample size for the planned analyses, some
of which were postponed until the following season. A total
of 575 households (96%) were included after the first pan-
demic season (September 7 to December 27, 2009 [23]).
Ethical considerations
The protocol of the CoPanFlu-France study was
approved by the research ethics committee “Comité de
Protection des Personnes Ile-de-France 1” on September
8, 2009. Information was previously given by investiga-
tors to participants indirectly through written descrip-
tions of the study and training of the nurses, and
directly by e-mail and telephone for any question. Writ-
ten informed consent was obtained for all subjects.
Discussion
Expected results
Many analyses have been recently completed or are cur-
rently being carried out. Based on inclusion data, we
used a data-driven approach to identify factors asso-
ciated with a high anti-H1N1pdm serological titer. We
are conducting several analyses to identify risk factors
Figure 3 Design of the study: systematic and additional visits of households by nurses.
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associated with influenza infections (based on serological
data for the first pandemic season, then on both sero-
logical and virological data for the following seasons).
Nasal swabs are being analyzed to identify various re-
spiratory viruses and the characteristics of infected sub-
jects. Blood samples collected during ILI visits are used
to study innate immunity against influenza and the
related transcriptome. Determinants of vaccination
against influenza have also been identified, and other
studies are being conducted in the field of social science
and risk perception. Several other analyses are expected
soon from different collaboration partners in various
biomedical fields.
Strengths of the study
The main strength of this cohort is the large amount of
available and expected data and the different biological
samples to be collected, which will permit to carry on
many studies in various biomedical fields. To our know-
ledge, this project is the first attempt to study so thor-
oughly the determinants of infections by respiratory
viruses in a large sample of households randomly
selected in the community. This approach is likely to
provide new insights from the interaction of sparse data
usually studied separately, especially with the help of
data-driven methods such as those already under devel-
opment in the field of non-communicable diseases
Figure 4 Main data collected on questionnaires at entry in the cohort, in addition to blood samples.
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[15,16]. Additional data is being collected and analyzed
in this ongoing cohort, whose longitudinal analysis will
permit integrative analyses of complex phenomena such
as individual, collective and environmental risk factors
of infection, routes of transmission, or determinants of
the immune response to infection or vaccination.
Limitations
We designed the CoPanFlu-France study in order to en-
able inference to the French general population, yet we
cannot exclude a selection bias induced by the propor-
tion of contacted households who refused to participate.
However, a comparison between CoPanFlu subjects and
population census data [20] suggests that this bias was
controlled (see supplementary material part 2).
We wish we were able to set up this project a few
months earlier, in order to include households before
and to follow-up subjects during the 2009 pandemic sea-
son. Due to organizational impairments, the inclusion
process was delayed and data regarding ILIs were col-
lected retrospectively, sometimes up to 6 months after
the epidemic. Thus, this timeline of inclusion may have
induced recall or reporting biases for the 2009 season,
and we were not able to collect enough pre-pandemic
blood samples and nasal swabs during this first
H1N1pdm season to investigate laboratory-confirmed
infections. Another consequence of this delayed inclu-
sion process is that we decided to stop inclusions as only
601 out of the 1000 expected households were included.
This limit is the main reason why we decided to post-
pone the end of the study until 2012 instead of 2011 as
initially expected, in order to collect data during an add-
itional influenza season.
Additional file
Additional file 1: Design and methods of the CoPanFlu-France
cohort: representativeness of the population sample.
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